Literature DB >> 21068207

Three-dimensional quantitative structure-activity relationship studies on UGT1A9-mediated 3-O-glucuronidation of natural flavonols using a pharmacophore-based comparative molecular field analysis model.

Baojian Wu1, John Kenneth Morrow, Rashim Singh, Shuxing Zhang, Ming Hu.   

Abstract

Glucuronidation is often recognized as one of the rate-determining factors that limit the bioavailability of flavonols. Hence, design and synthesis of more bioavailable flavonols would benefit from the establishment of predictive models of glucuronidation using kinetic parameters [e.g., K(m), V(max), intrinsic clearance (CL(int)) = V(max)/K(m)] derived for flavonols. This article aims to construct position (3-OH)-specific comparative molecular field analysis (CoMFA) models to describe UDP-glucuronosyltransferase (UGT) 1A9-mediated glucuronidation of flavonols, which can be used to design poor UGT1A9 substrates. The kinetics of recombinant UGT1A9-mediated 3-O-glucuronidation of 30 flavonols was characterized, and kinetic parameters (K(m), V(max), CL(int)) were obtained. The observed K(m), V(max), and CL(int) values of 3-O-glucuronidation ranged from 0.04 to 0.68 μM, 0.04 to 12.95 nmol/mg/min, and 0.06 to 109.60 ml/mg/min, respectively. To model UGT1A9-mediated glucuronidation, 30 flavonols were split into the training (23 compounds) and test (7 compounds) sets. These flavonols were then aligned by mapping the flavonols to specific common feature pharmacophores, which were used to construct CoMFA models of V(max) and CL(int), respectively. The derived CoMFA models possessed good internal and external consistency and showed statistical significance and substantive predictive abilities (V(max) model: q(2) = 0.738, r(2) = 0.976, r(pred)(2) = 0.735; CL(int) model: q(2) = 0.561, r(2) = 0.938, r(pred)(2) = 0.630). The contour maps derived from CoMFA modeling clearly indicate structural characteristics associated with rapid or slow 3-O-glucuronidation. In conclusion, the approach of coupling CoMFA analysis with a pharmacophore-based structural alignment is viable for constructing a predictive model for regiospecific glucuronidation rates of flavonols by UGT1A9.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21068207      PMCID: PMC3033718          DOI: 10.1124/jpet.110.175356

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

Review 1.  Beyond eyeballing: fitting models to experimental data.

Authors:  A Christopoulos; M J Lew
Journal:  Crit Rev Biochem Mol Biol       Date:  2000       Impact factor: 8.250

2.  Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9.

Authors:  Brian T Ethell; Sean Ekins; Jibo Wang; Brian Burchell
Journal:  Drug Metab Dispos       Date:  2002-06       Impact factor: 3.922

3.  Use of glucuronidation fingerprinting to describe and predict mono- and dihydroxyflavone metabolism by recombinant UGT isoforms and human intestinal and liver microsomes.

Authors:  Lan Tang; Ling Ye; Rashim Singh; Baojian Wu; Chang Lv; Jie Zhao; Zhongqiu Liu; Ming Hu
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

4.  Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs).

Authors:  M L Barreca; A Carotti; A Carrieri; A Chimirri; A M Monforte; M P Calace; A Rao
Journal:  Bioorg Med Chem       Date:  1999-11       Impact factor: 3.641

5.  Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates.

Authors:  Michael J Sorich; Paul A Smith; Ross A McKinnon; John O Miners
Journal:  Pharmacogenetics       Date:  2002-11

6.  Glucuronidation of flavonoids by recombinant UGT1A3 and UGT1A9.

Authors:  Yakun Chen; Shenggu Xie; Shuqing Chen; Su Zeng
Journal:  Biochem Pharmacol       Date:  2008-05-15       Impact factor: 5.858

Review 7.  Polyphenols, dietary sources and bioavailability.

Authors:  Massimo D'Archivio; Carmela Filesi; Roberta Di Benedetto; Raffaella Gargiulo; Claudio Giovannini; Roberta Masella
Journal:  Ann Ist Super Sanita       Date:  2007       Impact factor: 1.663

Review 8.  Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification.

Authors:  Takashi Iyanagi
Journal:  Int Rev Cytol       Date:  2007

9.  In silico and in vitro approaches to elucidate the thermal stability of human UDP-glucuronosyltransferase (UGT) 1A9.

Authors:  Ryoichi Fujiwara; Miki Nakajima; Tetsunori Yamamoto; Hidemi Nagao; Tsuyoshi Yokoi
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

10.  Structure and concentration changes affect characterization of UGT isoform-specific metabolism of isoflavones.

Authors:  Lan Tang; Rashim Singh; Zhongqiu Liu; Ming Hu
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

View more
  15 in total

1.  Accurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches.

Authors:  Baojian Wu; Xiaoqiang Wang; Shuxing Zhang; Ming Hu
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

Review 2.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

3.  Uridine diphosphate glucuronosyltransferase isoform-dependent regiospecificity of glucuronidation of flavonoids.

Authors:  Rashim Singh; Baojian Wu; Lan Tang; Ming Hu
Journal:  J Agric Food Chem       Date:  2011-06-06       Impact factor: 5.279

Review 4.  Regioselective sulfation and glucuronidation of phenolics: insights into the structural basis.

Authors:  Baojian Wu; Sumit Basu; Shengnan Meng; Xiaoqiang Wang; Ming Hu
Journal:  Curr Drug Metab       Date:  2011-11       Impact factor: 3.731

Review 5.  Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes.

Authors:  Dong Dong; Roland Ako; Ming Hu; Baojian Wu
Journal:  Xenobiotica       Date:  2012-03-02       Impact factor: 1.908

6.  Evaluation of 3,3',4'-trihydroxyflavone and 3,6,4'-trihydroxyflavone (4'-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1.

Authors:  Baojian Wu; Shuxing Zhang; Ming Hu
Journal:  Mol Pharm       Date:  2011-10-21       Impact factor: 4.939

7.  Absolute quantification of UGT1A1 in various tissues and cell lines using isotope label-free UPLC-MS/MS method determines its turnover number and correlates with its glucuronidation activities.

Authors:  Beibei Xu; Song Gao; Baojian Wu; Taijun Yin; Ming Hu
Journal:  J Pharm Biomed Anal       Date:  2013-08-29       Impact factor: 3.935

8.  Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes.

Authors:  Michael J Osborne; Luciana Coutinho de Oliveira; Laurent Volpon; Hiba Ahmad Zahreddine; Katherine L B Borden
Journal:  J Mol Biol       Date:  2018-11-11       Impact factor: 5.469

9.  SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent.

Authors:  Chiara Borsari; Nuno Santarem; Sara Macedo; María Dolores Jiménez-Antón; Juan J Torrado; Ana Isabel Olías-Molero; María J Corral; Annalisa Tait; Stefania Ferrari; Luca Costantino; Rosaria Luciani; Glauco Ponterini; Sheraz Gul; Maria Kuzikov; Bernhard Ellinger; Birte Behrens; Jeanette Reinshagen; José María Alunda; Anabela Cordeiro-da-Silva; Maria Paola Costi
Journal:  ACS Med Chem Lett       Date:  2019-01-29       Impact factor: 4.345

10.  Revolving door action of breast cancer resistance protein (BCRP) facilitates or controls the efflux of flavone glucuronides from UGT1A9-overexpressing HeLa cells.

Authors:  Yingjie Wei; Baojian Wu; Wen Jiang; Taijun Yin; Xiaobin Jia; Sumit Basu; Guangyi Yang; Ming Hu
Journal:  Mol Pharm       Date:  2013-04-23       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.